66-Country Survey Exposes Barriers to Hemophilia Gene Therapy
Wolfgang Miesbach, Professor of Medicine at Frankfurt University Hospital, posted on LinkedIn:
”Haemophilia Gene Therapy: New ISTH survey reveals a critical disconnect between clinical innovation and healthcare readiness.
Global survey assessing knowledge, perceptions, and clinical preparedness for gene therapy among haemophilia professionals. Over eight months (August 2023–January 2024), 327 healthcare professionals from 66 countries responded via an anonymous online questionnaire distributed through four major professional organizations.
Current Therapy Limitations
– burden of dosing schedules and prophylaxis
– of inhibitor development
– with injections and venous access
– and reimbursement pressures
– with treatment adherence
– impact on quality of life and joint disease
– breakthrough bleeding and pain
What Was Found Related to Gene Therapy
– 7.5% feel extremely familiar with gene therapy
– 35.6% uncomfortable answering patient questions about trials
– 60% of patients have never discussed gene therapy with their care team
Major Barriers to Implementation of Gene Therapy
– Durability uncertainty
– Variability in patient response
– Cost and reimbursement challenges
– Restrictive eligibility criteria
– Insufficient healthcare system preparedness
Gene therapy is clinically available. What’s missing is confidence, system readiness, and equitable global access. Closing this gap requires targeted professional education, healthcare pathways, and solutions that ensure all eligible patients – ideally, regardless of geography – can access this transformative treatment.
Published in Therapeutic Advances in Hematology, open access link ”
Title: Gene therapy for hemophilia: results of ISTH global survey on current knowledge, attitudes, and preparedness of the hemophilia care team
Authors: Melissa F. Glasner, Wolfgang Miesbach

Stay informed with Hemostasis Today.
-
Mar 6, 2026, 16:51Priya Reehal: Highlighting The Central Role of Nurses in Cardio-Oncology
-
Mar 6, 2026, 16:50Rainer Kaiser: Blinatumomab Shows Remarkable Response in Multi-Refractory ITP and APS
-
Mar 6, 2026, 16:18Laila Shalabi: Clopidogrel, Aspirin, and the Role of PPIs in Coronary Artery Disease
-
Mar 6, 2026, 16:17Paul McKenzie: The Value of Gene Therapy in Bleeding Disorders
-
Mar 6, 2026, 16:15Basma El Homasany: The ‘Little Brain’ of the Heart and Its Role in Health
-
Mar 6, 2026, 16:14Jamal Rana: Family History and Polygenic Risk for Coronary Heart Disease
-
Mar 6, 2026, 15:43Kristy Ainslie: Breaking Down the Discovery and FDA Approval of Drug Carriers
-
Mar 6, 2026, 15:18Claudio Laudani: Efficacy and Safety of Colchicine for Secondary Prevention in Coronary Artery Disease
-
Mar 6, 2026, 15:09Chris Simon: Persona PLUS Receives FDA Clearance for Patent‑Protected Plasma Apheresis